<DOC>
	<DOC>NCT02201953</DOC>
	<brief_summary>The primary objectives of this study are to compare the efficacy of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks with that of sofosbuvir (SOF) + ribavirin (RBV) for 24 weeks and to evaluate the safety and tolerability of each treatment regimen in participants with chronic genotype 3 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing and able to provide written informed consent HCV RNA ≥ 10^4 IU/mL HCV genotype 3 Chronic HCV infection (≥ 6 months) Females of childbearing potential must have a negative serum pregnancy test Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception Current or prior history of clinicallysignificant illness (other than HCV) that may interfere with subject treatment, assessment or compliance with the protocol Screening ECG with clinically significant abnormalities Laboratory results outside of acceptable ranges at Screening Pregnant or nursing female or male with pregnant female partner Chronic liver disease of a nonHCV etiology (e.g., hemochromatosis, Wilson's disease, alfa1 antitrypsin deficiency, cholangitis) Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Sofosbuvir</keyword>
	<keyword>Velpatasvir</keyword>
	<keyword>SOF/VEL</keyword>
	<keyword>GS-5816</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Genotype 3</keyword>
</DOC>